CN1187822A - 青毒素g苯脂的改进制备方法 - Google Patents
青毒素g苯脂的改进制备方法 Download PDFInfo
- Publication number
- CN1187822A CN1187822A CN96194750A CN96194750A CN1187822A CN 1187822 A CN1187822 A CN 1187822A CN 96194750 A CN96194750 A CN 96194750A CN 96194750 A CN96194750 A CN 96194750A CN 1187822 A CN1187822 A CN 1187822A
- Authority
- CN
- China
- Prior art keywords
- salt
- compound
- general formula
- expression
- penicillin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Natural products N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 title claims abstract description 54
- 229940056360 penicillin g Drugs 0.000 title claims abstract description 32
- 238000000034 method Methods 0.000 title claims abstract description 25
- -1 penicillin G phenyl ester Chemical class 0.000 title claims description 14
- 150000003839 salts Chemical class 0.000 claims abstract description 52
- 150000001875 compounds Chemical class 0.000 claims abstract description 45
- 238000006243 chemical reaction Methods 0.000 claims abstract description 26
- 238000002360 preparation method Methods 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000005917 acylation reaction Methods 0.000 claims description 5
- 239000000376 reactant Substances 0.000 claims description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 48
- 235000002639 sodium chloride Nutrition 0.000 description 43
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- 238000002425 crystallisation Methods 0.000 description 20
- 230000008025 crystallization Effects 0.000 description 20
- 238000003756 stirring Methods 0.000 description 20
- 239000001301 oxygen Substances 0.000 description 19
- 229910052760 oxygen Inorganic materials 0.000 description 19
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 17
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 17
- 239000012044 organic layer Substances 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 238000001035 drying Methods 0.000 description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 14
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 10
- 239000013078 crystal Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 239000004105 Penicillin G potassium Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
- 235000019368 penicillin G potassium Nutrition 0.000 description 7
- 239000012266 salt solution Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 5
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- IAVREABSGIHHMO-UHFFFAOYSA-N 3-hydroxybenzaldehyde Chemical compound OC1=CC=CC(C=O)=C1 IAVREABSGIHHMO-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 238000007670 refining Methods 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000008065 acid anhydrides Chemical class 0.000 description 3
- 239000012675 alcoholic extract Substances 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 238000002386 leaching Methods 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 2
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical class CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000005660 chlorination reaction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 238000000622 liquid--liquid extraction Methods 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- FDRVTDDJHPPAGK-UHFFFAOYSA-N n,n-dimethylformamide;thionyl dichloride Chemical compound ClS(Cl)=O.CN(C)C=O FDRVTDDJHPPAGK-UHFFFAOYSA-N 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 229940086542 triethylamine Drugs 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- UWHSPZZUAYSGTB-UHFFFAOYSA-N 1,1,3,3-tetraethylurea Chemical compound CCN(CC)C(=O)N(CC)CC UWHSPZZUAYSGTB-UHFFFAOYSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- OKVJCVWFVRATSG-UHFFFAOYSA-N 3-hydroxybenzyl alcohol Chemical compound OCC1=CC=CC(O)=C1 OKVJCVWFVRATSG-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001262 acyl bromides Chemical class 0.000 description 1
- 150000001263 acyl chlorides Chemical group 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- IAQRGUVFOMOMEM-UHFFFAOYSA-N butene Natural products CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical class [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Substances ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-M glutaminate Chemical compound [O-]C(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-M 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- LSACYLWPPQLVSM-UHFFFAOYSA-N isobutyric acid anhydride Chemical compound CC(C)C(=O)OC(=O)C(C)C LSACYLWPPQLVSM-UHFFFAOYSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- UHAAFJWANJYDIS-UHFFFAOYSA-N n,n'-diethylmethanediimine Chemical compound CCN=C=NCC UHAAFJWANJYDIS-UHFFFAOYSA-N 0.000 description 1
- AJFDBNQQDYLMJN-UHFFFAOYSA-N n,n-diethylacetamide Chemical compound CCN(CC)C(C)=O AJFDBNQQDYLMJN-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D499/04—Preparation
- C07D499/08—Modification of a carboxyl radical directly attached in position 2, e.g. esterification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D499/21—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a nitrogen atom directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D499/44—Compounds with an amino radical acylated by carboxylic acids, attached in position 6
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cephalosporin Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
一种制备通式I:表示的青毒素G苯脂或者其盐的新方法,由通式Ⅱ:表示的化合物或者其盐与通式Ⅲ:表示的化合物或者其盐反应。
Description
技术领域
本发明涉及青毒素G苯脂的改进制备方法。更详细地说,是涉及适用于工业生产的经由新的中间体化合物,制备青毒素G苯脂的方法。
技术背景
本发明的目的化合物(I),例如,用作鱼的链球菌症的治疗剂,对鱼体有着很好的经口吸收的效果,其制备方法,已知有按照如下路线进行的方法(PCT/JP92/01327)
但是采用这种方法,由于需要处理作为中间体的具有不稳定的青毒素骨架、并对人体有变态反应性的上述化合物(B)和(C),这对于操作者存在安全性的问题。
发明说明
本发明者们,对于安全并且适用于工业生产的优良的制备方法进行刻意地研究结果发现了,经由下述的新化合物中间体(II)、(IIa)制备青毒素G苯脂的安全并且适用于工业生产的优良的制备方法。
同以往的方法中的上述中间体(B)、(C)相比,本发明中的下述中间体(II)、特别是下述中间体(IIa)由于分子量小,中间工序所需的反应容器容积小,有利于操作。
本发明的目的化合物(I)由通式:表示本发明的目的化合物(I)是由通式:表示的化合物或者其盐通过酰化反应得到通式:表示的化合物或者其盐,然后与通式:表示的化合物或者其盐反应,来制备通式:表示的化合物或者其盐。
依照本发明,可按照如下方法制备目的化合物(I)。制备方法1
(III) (II)或者其盐 或者其盐制备方法2
(IV) (II)或者其盐 或者其盐或者其盐
作为目的化合物(I)的合适的医药上容许的盐,可列举的有,常用的无毒性的盐,酸修饰的盐。具体地有,无机酸修饰盐(例如,盐酸盐,氢溴酸盐、硫酸盐、磷酸盐等),有机羧酸修饰盐或者有机磺酸修饰盐(例如,甲酸盐,乙酸盐、三氟乙酸盐、乙二酸盐、顺丁烯二酸盐、反丁烯二酸盐、洒石酸盐、甲磺酸盐,苯磺酸盐、对-甲苯磺酸盐等)酸性氨基酸的盐(例如,天冬氨酸盐、谷氨酸盐等)。实施发明的优选方案以下详细说明目的化合物(I)的制备方法。制备方法1
化合物(II)或者其盐,可由化合物(III)或者其盐的醇羟基通过选择性酰化反应制得。
作为化合物(II)和化合物(III)的合适的盐,可列举的有,与无机碱所成的盐、例如碱金属盐(例如、钠盐、钾盐、铯盐等)、碱土类金属盐(例如、钙盐、镁盐等)、铵盐;与有机碱所成的盐、例如有机胺盐(例如、三甲基胺盐、三乙基胺盐、吡啶盐、甲基吡啶盐、乙醇胺盐、三乙醇胺盐、二环己基胺盐、N,N′-二苄基亚乙基二胺盐等)等等。
适合的酰卤化物,可举出的是酰氯,酰溴等。
适合的“酸酐”,可举出的是链烷酸酐(例如乙酸酐等),链烯酸酐(例如2-丁烯酸酐等)等等。
象化合物(III)那样,一个分子内含有酚性和醇性的二种羟基的化合物,在酸性或者中性的条件下,醇羟基被优先酰化。这时,如果并用作为脱氧剂的酰胺衍生物(例如,N,N-二甲基乙酰胺,N,N-二乙基乙酰胺、N,N-二甲基丙酰胺、N-甲基-2-吡咯烷酮。N-甲基乙酰苯胺、四甲基尿素、四乙基尿素等)进行反应时,可以提高醇羟基的酰化选择性。其中,特别优选的是N-甲基-2-吡咯烷酮。
反应通常在丙酮、二恶烷、四氢呋喃、乙醚、二异丙基醚、乙腈、氯仿、二氯甲烷、二氯乙烷、乙酸乙酯、N,N-二甲基甲酰胺、甲苯等常用的溶剂或者它们的混合物中进行,也可在对反应无不良影响的任意的其它有机溶剂中进行。
反应温度无特殊限制,反应通常在冷却下,室温或者加热下进行。制备方法2
目的化合物(I)或者其盐可由化合物(IV)或者其盐与化合物(II)或者其盐反应进行制备。
化合物(IV)的适合的盐。可举出与化合物(II)所示的相同的盐。
本反应通常在碳化二亚胺类(例如N,N′-二环己基碳化二亚胺、N-环己基-N′-吗啉代乙基碳化二亚胺、N-环己基-N′-(4-二乙胺基环己基)碳化二亚胺、N,N′-二乙基碳化二亚胺、N,N′-二异丙基碳化二亚胺、N-乙基-N′-(3-二甲胺基丙基)碳化二亚胺等);三唑类(例如1-(对-氯苯磺酰氧基)-6-氯-1H-苯并三唑、N-羟基苯并三唑等);卤化吡啶盐(例如碘化2-氯-1-甲基吡啶盐等);氰尿酰氯-吡啶洛合物,亚硫酰氯-二甲基甲酰胺(Bylsmiya(音译)试剂)、甲磺酰氯等常用的缩合剂存在下或者按照混合酸酐法等常用的酯化方法进行。这些缩合剂中,特别优选的是氰尿酰氯一吡啶络合物、亚硫酰氯-二甲基甲酰胺(Bylsmiya(音译)试剂)N,N′-二环己基碳化二亚胺等。
本反应通常在,碱金属氢氧化物(例如、氢氧化钠、氢氧化钾等),碱金属碳酸盐(例如、碳酸钠、碳酸钾等),碱金属碳酸氢盐(例如、碳酸氢钠、碳酸氢钾等)、三(低级)烷基胺(例如、三甲胺、三乙胺等)、吡啶或者其衍生物(例如、甲基吡啶、二甲基吡啶、4-二甲胺基吡啶等)、N-(低级)烷基吗啉、N,N-二(低级)烷基苄胺等那样的无机或者有机碱的存在下进行。
反应通常在、二噁烷、四氢呋喃、乙醚、二异丙基醚、乙腈、氯仿、二氯甲烷、二氯乙烷、乙酸乙酯、N,N-二甲基甲酰胺等的常用溶剂中、或者对反应无不良影响的任何其它有机溶剂中进行。
当所用的缩合剂或者碱是液体时,也可将其作为溶剂使用。
反应温度无特殊限制,反应通常在冷却下,室温或者加热下进行。
上述制备方法所得的化合物,可用萃取。沉淀、分别结晶、再结晶、减压蒸馏、色谱法等常用的方法分离,精制。
本发明的方法与以往众所周知的方法相比较,可以提供安全并且适用于工业生产的优良的青毒素G苯脂(I)的制备方法。
加上上述的收率的提高,本发明的方法与以往的方法相比,有如下优点。即,以往的方法的中间体(B)不能结晶化、作为所得到的油状物很难蒸馏、所以在精制时,不得不采用不适合于工业生产的硅胶柱色谱法。另一方面,本发明中的中间体(D)虽然也是油状物,却可以用减压蒸馏(bp.150℃/0.4乇)很容易地精制。
如上所述,本发明的方法与以往的方法相比在收率、操作性、经济性(本发明方法的中间体(E)、(D)与以往方法的中间体(B)、(C)相比由于分子量小,同摩尔比的反应容量也小)等方面均好。
制备例1
将3-羟基苯甲醛(20.1g)悬浮在水(41ml)中,氮气气流下20~30℃加入硼氢化钠(1.65g),搅拌30分钟。温度20℃以下缓缓加入浓盐酸(约2.5ml)调pH值为7。加入乙酸乙酯41ml和食盐(11.5g)并进行萃取。有机层用无水硫酸镁(10g)干燥后,残液减压浓缩至30ml,加入正-庚烷205ml使析出结晶。滤取析出的结晶,减压干燥后,得到3-羟基苯甲醇白色结晶(20.2g,收率99%)。制备例2
将青毒素G钾(10.0)悬浮在吡啶(50ml)中,用液化氮气冷却至-20°~-10℃,滴加氰尿酰氯(5.71g)的四氢呋喃(40ml)溶液。同温度下再滴加3-羟基苯甲醛(2.76g),用四氢呋喃(10ml)清洗合并。-5°~0℃下搅拌2小时30分钟后,加入乙酸乙酯(100ml)水(150ml)、分液、有机层用冰冷却的2N-盐酸(100ml)与食盐(20g)的混合溶液洗涤2次。再用冰冷却的水(100ml)、碳酸氢钠(5.0g)、食盐(8.0g)的混合溶液洗涤1次,饱和食盐水(50ml)洗涤2次,有机层用无水硫酸镁干燥后,用活性炭脱色、减压浓缩得到14.49g残渣。用液相色谱法定量其含量时发现,生成8.59g(收率87%)的青霉素G的3-甲酰基苯酯。制备例3
青霉素G的3-甲酰基苯酯(8.6g)的乙酸乙酯溶液(16.25g)中加入甲醇40ml并冷却至-20°~-10℃,加入硼氢化钠(209mg)搅拌、-10°~-0℃下滴入水(50ml),使结晶析出。滤取析出的结晶、减压干燥后得到青霉素G的3-羟甲基苯脂白色结晶(7.94g:收率92%)。制备例4
将青霉素G的3-羟甲基酚(7.68g)与4-二甲胺基吡啶(52mg)与二甲基甲酰胺(5ml)的混合物冷却至10℃以下,加入异丁酸酐(2.96g)。25℃下搅拌2小时,加入异丙醇(27ml)并过滤反应液。滤液中再次加入异丙醇50ml,加入种晶搅拌。滴加水(120ml)使结晶析出。滤取析出的结晶减压干燥后得到白色结晶的青毒素G的3-异丁酰氧甲基苯脂(8.14g;94%)以下,举实施例说明。实施例1
将3-羟基苯甲醇(8.0g)溶于四氢呋喃(20ml)中,维持此溶液内温不超过30℃条件下滴加氯化异丁酸(8.9g)。反应液中加入饱和食盐水(40ml)停止反应、分液得到有机层,用饱和食盐水(40ml)和饱和碳酸氢钠水溶液(40ml)分别洗涤2次,再用饱和食盐水(40ml)洗涤1次。有机层用无水硫酸镁干燥后,减压浓缩,得到3-异丁酰氧甲基苯酚(12.8g)油状物。
IR(石蜡糊):3325,1697,1587cm-1
NMR(CDCl3,δ):1.47(6H,d,J=7.0Hz),2.61(1H,hep,J=7.0Hz),5.07(2H,s),5.40(1H,s),6.7-6.9(3H,m),7.22(1H,t,J=7.7Hz)实施例2
将3-羟基苯甲醇(25.1g)、N-甲基-2-吡咯烷酮(32.0g)和二氯甲烷(150ml)的混合物冷却至10℃。向其中经15分钟滴加氯化异丁酸(25.7g)。滴加结束后,室温下再搅拌30分钟。反应液中加入稀氢氧化钠溶液调pH值为6。再加入二氯甲烷萃取,分离出有机层。有机层用水和饱和碳酸氢钠水溶液充分洗涤3~5次,减压浓缩。得到大约40g的油状残渣。用硅胶柱色谱法(展开溶剂:正-己烷-乙酸乙酯4∶1~3∶1)精制,得到3-异丁酰氧甲基苯酚(32.6g)油状物。实施例3
青毒素G钾(60.0g)和吡啶(29.7g)的混合物在氮气中保持在-10~-20℃下边搅拌边滴入。然后,保持在同温度下滴入3-异丁酰氧甲基苯酚(26.0g)滴加结束后,维持温度在-20°~0℃,再搅拌1小时。反应液中加入水(400ml)、乙酸乙酯(350ml)稀盐酸调pH值为3,萃取。分离出的有机层用饱和碳酸氢钠水溶液洗涤两次,用无水硫酸钠干燥。浓缩。所得的油状物中加入二异丙基醚,搅拌使析出结晶。过滤得到粗结晶,加入甲醇(500ml)加热溶解,用活性炭处理、浓缩、再次加入异丙醚使析出结晶、过滤得到青毒素G的3-异丁酰氧甲基苯脂(52.6g)的白色结晶。
NMR(CDCl3,δ):1.19(6H,d,J=7.0Hz),1.53(3H,s),1.63(3H,s),2.61(1H,hep,J=7.0Hz),3.66(2H,s),4.60(1H,s),5.11(2H,s),5.56(1H,d,J=4.2Hz),5.70(1H,dd,J=4.2,9.01Hz),6.10(1H,d,J=9.0Hz),7.0-7.5(9H,m)实施例4
青毒素G钾(60.0g)和吡啶(300ml)的混合物在氮气中保持-10~-20℃,搅拌下滴入氰尿酰氯(29.7g)的二氯甲烷(180ml)溶液。接着,维持同一温度滴入3-异丁酰氧甲基苯酚(26.0g)。滴加结束后,在-20~0℃温度下,再搅拌1小时。于反应液中加入水(400ml)、乙酸乙酯(350ml)、稀盐酸、调节pH值为3并进行萃取。分离出的有机层用饱和碳酸氢钠水溶液洗涤2次,用无水硫酸钠干燥后,浓缩。往所得的油状物中加入二异丙基醚(400ml),搅拌使析出结晶。过滤得到的粗结晶,在甲醇(500ml)中加温溶解,用活性碳(5g)处理后,浓缩,再次加入二异丙基醚(250ml)使析出结晶,过滤得到青毒素G的3-异丁酰氧甲基苯脂(52.6g)白色结晶。
IR(石蜡糊):3370,1780,1770,1760,1730,1686,1516cm-1
NMR(CDCl3,δ):119(6H,d,J=7.0Hz),1.53(3H,s),1.63(3H,s),2.61(1H,hep,J=7.0Hz),3.66(2H,s),4.60(1H,s),5.11(2H,s),5.56(1H,d,J=4.2Hz),5.70(1H,dd,J=4.2,9.01Hz),6.10(1H,d,J=9.0Hz),7.0-7.5(9H,m)实施例5
青毒素G钾(6.2g)与3-异丁酰氧甲基苯酚(2.5g)和碘化2-氯-1-甲基吡啶(4.3g)于二氯甲烷(40ml)中成悬浊液,并于室温下搅拌、保持悬浊液内温35℃以下滴加三乙基胺(1.7g)。滴加结束后,室温下搅拌30分钟。反应液减压浓缩后,所得的残渣用水(60ml)与乙酸乙酯(60ml)液-液萃取,水层再用乙酸乙酯(30ml)萃取。合并有机层,用水(30ml)清洗1次,用硫酸钠干燥,减压浓缩。所得的油状物用硅胶柱色谱法(硅胶100g:展开溶剂∶乙酸乙酯-正-己烷=1∶2)精制,得到青毒素G的3-异丁酰氧甲基苯酯(3.43g)白色结晶。该目的化合物的常数与实施例4的常数一致。实施例6
青毒素G钾(6.1g)与3-异丁酰氧甲基苯酚(2.5g)与N,N′-二环己基碳化二亚胺(3.5g)于四氢呋喃(40ml)中成悬浊液,加入4-二甲胺基吡啶(70mg)。室温下搅拌,保持悬浊液内温25~35℃滴加4N-盐酸乙酸乙酯(4ml)。滴加结束后,室温下搅拌30分钟,反应液减压过滤。滤液减压浓缩后,所得残渣用水(70ml)与乙酸乙酯(70ml)液-液萃取,分离得到的乙酸乙酯层,用无水硫酸钠干燥后,减压浓缩。所得的油状物用硅胶柱色谱法(硅胶70g:展开溶剂∶乙酸乙酯-正-己烷=1∶2)精制,得到青毒素G的3-异丁酰氧甲基苯酯(5.22g)白色结晶。该目的化合物的常数与实施例4的常数一致。实施例7
青毒素G钾盐(4.60g)的二氯甲烷(18ml)悬浊液冷却至-5℃以下,维持-5℃,搅拌下顺次加入N-甲基吗啉(1.2ml)、甲磺酰氯(1.4ml)。保持温度0℃以下搅拌90分钟。在温度0~-5℃下滴加3-异丁酰氧甲基苯酚(2.21g)。用二氯甲烷(4ml)清洗滴加漏斗并入反应液中。保持温度0~-5℃搅拌2小时。反应液中加入水(14ml),分液得到有机层。有机层用5%柠檬酸、25%食盐水溶液,10%碳酸氢钠水溶液,25%食盐水溶液,水(各14ml)顺次洗涤,用无水硫酸镁干燥后,减压浓缩、干燥成固体。粗结晶用乙酸乙酯9ml溶解,滴加正-庚烷(46ml),使析出结晶。过滤,减压干燥后,得到青毒素G的3-异丁酰氧甲基苯酯白色结晶(2.63g)。该目的化合物的常数与实施例4的常数一致。实施例8
温度0℃以下往二甲基甲酰胺(30ml)中加入亚硫酰氯(7.35g),充分搅拌。然后保持温度0℃以下持续搅拌,顺次加入青毒素G钾(21.10g)、3-异丁酰氧甲基苯酚(10.94g)、吡啶(9.76g)。温度-10~0℃下搅拌30分钟后,加入乙酸乙酯(100ml)然后再加入20%食盐水(100ml)并进行分液。有机层用20%食盐水、10%柠檬酸-20%食盐(1∶1)混合液,5%碳酸氢钠水溶液-20%食盐水(1∶1)混合液,20%食盐水(各100ml),顺次洗涤。有机层减压浓缩后,得到油状物残渣。将此油状物溶解于异丙醇(100ml)中,温度20~25℃搅拌下加入种晶,滴加水(150ml)、使析出结晶。过滤得到结晶、减压干燥后,得到青毒素G的3-异丁酰氧甲基苯酯(24.3g)。该目的化合物的常数与实施例4的常数一致。实施例9
将氰尿酰氯(3.70g)与乙酸乙酯(54ml)的混合物冷却至-10~-5℃。同温搅拌下,滴加吡啶(7.94g)。充分搅拌后,顺次加入二甲基甲酰胺(27ml)、青毒素G钾盐(6.90g)、3-异丁酰氧甲基苯酚(3.0g)、在温度-10~-5℃下持续搅拌5小时。反应液温度升至室温后,用5%柠檬酸、10%食盐水(各60ml)清洗2次,用2.5%碳酸氢钠水溶液、10%食盐水,水(各60ml)清洗一次。有机层减压浓缩至干燥固态。保持温度20~25℃下,将残渣溶于异丙醇(30ml)中,加入种晶,搅拌30分钟,然后滴加水(45ml)使析出结晶。过滤后干燥,得到青毒素G的3-异丁酰氧甲基苯脂白色结晶(6.95g)。该目的化合物的常数与实施例4的常数一致。实施例10
青毒素G钾(2.0kg)与吡啶(10L)的混合物在氮气下冷却至15℃。搅拌下加入氰尿酰氯(1.1kg)的四氢呋喃(8L)溶液、保持溶液内温-10~-20℃下进行搅拌。然后,保持同一温度下滴加3-异丁酰氧甲基苯酚(0.89kg)。滴加结束后在-5~0℃下搅拌2.5小时。于反应液中加入乙酸乙酯20L,顺次用水(30L)清洗1次,冰冷却的稀盐酸的食盐水(22L)清洗2次,10%碳酸氢钠水溶液(10L)清洗2次,饱和食盐水(10L)清洗1次。有机层干燥(无水硫酸镁)后、加入活性碳过滤。减压浓缩,在残渣约为4L时加入N-己烷22L使析出结晶,过滤析出的结晶得到青毒素G的3-异丁酰氧甲基苯脂白色结晶(2.0kg)该目的化合物的常数与实施例4的常数一致。
Claims (8)
3.权利要求1的制备方法,其中在酸性或者中性条件下,在脱氧剂存在下进行反应。
4.权利要求2的制备方法,其中反应是在缩合剂存在下进行。
8.一种通式:表示的化合物或者其盐。
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP147528/95 | 1995-06-14 | ||
| JP14752895 | 1995-06-14 | ||
| JP8078296 | 1996-03-07 | ||
| JP80782/96 | 1996-03-07 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1187822A true CN1187822A (zh) | 1998-07-15 |
| CN1092661C CN1092661C (zh) | 2002-10-16 |
Family
ID=26421757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN96194750A Expired - Fee Related CN1092661C (zh) | 1995-06-14 | 1996-06-13 | 青毒素g苯酯的改进制备方法 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0837066B1 (zh) |
| JP (1) | JP3377795B2 (zh) |
| KR (1) | KR100402595B1 (zh) |
| CN (1) | CN1092661C (zh) |
| AT (1) | ATE248841T1 (zh) |
| DE (1) | DE69629815T2 (zh) |
| DK (1) | DK0837066T3 (zh) |
| ES (1) | ES2205034T3 (zh) |
| PT (1) | PT837066E (zh) |
| WO (1) | WO1997000259A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5419119B2 (ja) * | 2007-08-20 | 2014-02-19 | 国立大学法人名古屋大学 | エステルの製造法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD150393A3 (de) * | 1978-04-05 | 1981-09-02 | Wolfgang Krueger | Verfahren zur herstellung halbsynthetischer penicilline und ihrer alkalisalze |
| US5112967A (en) * | 1990-04-27 | 1992-05-12 | Hoffmann-La Roches Inc. | Process for synthesizing antibacterial cephalosporin compounds |
| JP2952015B2 (ja) * | 1990-08-28 | 1999-09-20 | 大塚化学株式会社 | ペニシリン類のエステル化方法 |
| JP2674315B2 (ja) * | 1991-10-15 | 1997-11-12 | 藤沢薬品工業株式会社 | ペニシリンgエステル |
-
1996
- 1996-06-13 WO PCT/JP1996/001604 patent/WO1997000259A1/ja active IP Right Grant
- 1996-06-13 PT PT96917662T patent/PT837066E/pt unknown
- 1996-06-13 CN CN96194750A patent/CN1092661C/zh not_active Expired - Fee Related
- 1996-06-13 KR KR1019970708137A patent/KR100402595B1/ko not_active Expired - Fee Related
- 1996-06-13 ES ES96917662T patent/ES2205034T3/es not_active Expired - Lifetime
- 1996-06-13 DE DE69629815T patent/DE69629815T2/de not_active Expired - Fee Related
- 1996-06-13 EP EP96917662A patent/EP0837066B1/en not_active Expired - Lifetime
- 1996-06-13 JP JP50291397A patent/JP3377795B2/ja not_active Expired - Fee Related
- 1996-06-13 AT AT96917662T patent/ATE248841T1/de not_active IP Right Cessation
- 1996-06-13 DK DK96917662T patent/DK0837066T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| EP0837066B1 (en) | 2003-09-03 |
| WO1997000259A1 (fr) | 1997-01-03 |
| ATE248841T1 (de) | 2003-09-15 |
| DK0837066T3 (da) | 2003-11-24 |
| EP0837066A4 (en) | 1998-11-25 |
| ES2205034T3 (es) | 2004-05-01 |
| CN1092661C (zh) | 2002-10-16 |
| DE69629815D1 (de) | 2003-10-09 |
| KR100402595B1 (ko) | 2005-09-02 |
| DE69629815T2 (de) | 2004-04-08 |
| JP3377795B2 (ja) | 2003-02-17 |
| KR19990014793A (ko) | 1999-02-25 |
| EP0837066A1 (en) | 1998-04-22 |
| PT837066E (pt) | 2004-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR860000343B1 (ko) | 클라불란산 및 약제학적으로 허용되는 그의 염을 제조하는 방법 | |
| CN102199111B (zh) | 制备丙型肝炎病毒蛋白酶抑制剂的方法和中间体 | |
| NO163897B (no) | Fremgangsmaate ved fremstilling av et terapeutisk aktivt (6r,7r)-3-karbamoyloksymetyl-7-((z)-2-(fur-2-yl)-2-metoksyiminoacetamido)-ceph-3-em-4-karboksylsyre-1-acetoksyetylester (cefuroksimaksetil). | |
| JPH09507235A (ja) | ロイコトリエン拮抗物質の調製方法 | |
| BG61306B1 (en) | Method for the preparation and/or purification of clavulanic acid and its pharmaceutically acceptable salt | |
| JPH11500753A (ja) | パクリタキセルおよびセファロマンニンの分離および精製 | |
| JP2009519245A (ja) | エキノカンジン型化合物の精製方法 | |
| CA2196450A1 (fr) | Forme purifiee de streptogramines, sa preparation et les compositions pharmaceutiques qui la contiennent | |
| US12157744B2 (en) | Compounds and methods of their manufacturing | |
| DE69330747T2 (de) | Desosamino-derivate von makroliden als immunosuppressive und antifungale mittel | |
| CA2376698A1 (fr) | Derives de streptogramines, leur preparation et les compositions qui les contiennent | |
| CN1041933C (zh) | 克拉维酸的二胺盐及其制备方法和用途 | |
| DK152126B (da) | Fremgangsmaade til isolering af pseudomonsyre | |
| CN1187822A (zh) | 青毒素g苯脂的改进制备方法 | |
| WO2011153221A1 (en) | Solid state forms of ixabepilone | |
| DE2624789B2 (de) | Eburnameninderivate | |
| JPS6228154B2 (zh) | ||
| AU758294B2 (en) | Method for preparation of pharmaceutical-grade dithiocarbamate | |
| AU2005263761A1 (en) | Improved process for the manufacture of mirtazapine | |
| DE60109496T2 (de) | Streptograminderivate, deren herstellung und zusammensetzungen, die diese verbindungen enthalten | |
| KR0163211B1 (ko) | 3-비닐세팔로스포린산 유도체의 제조방법 | |
| DE69821757T2 (de) | Verfahren zur herstellung von 6-0-monoestern von castanospermine | |
| CN120794897A (zh) | 一种依伏卡塞原料药的纯化方法 | |
| CN118255695A (zh) | 一种β-内酰胺类化合物的中间体的纯化方法和制备方法 | |
| RU2064929C1 (ru) | СПОСОБ ПОЛУЧЕНИЯ 2-(α -ГИДРОПОЛИФТОРАЛКИЛ)БЕНЗИМИДАЗОЛОВ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: FUJISAWA PHARMACEUTICAL CO Free format text: FORMER OWNER: FUJISAWA PHARMACEUTICAL CO., LTD. Effective date: 20020617 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20020617 Patentee after: Fujisawa Brown Animal Health Care Co., Ltd. Patentee before: Fujisawa Pharmaceutical Co., Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20021016 Termination date: 20120613 |